Engineered immune cells take on Hard-to-Treat breast cancer
NCT ID NCT06347068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new type of immune cell therapy called CAR-T cells that target a protein called B7-H3 on triple-negative breast cancer cells. The cells also have a safety switch to stop them if needed. Up to 42 adults whose cancer has returned or not responded to treatment will receive these cells along with two chemotherapy drugs. The main goal is to find a safe dose and understand side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iC9-CAR.B7-H3 T cells (a type of immune cell therapy) given with chemotherapy drugs cyclophosphamide and fludarabine
What this could lead to
If it works, this could point toward a new treatment option for people with triple-negative breast cancer that has come back or not responded to other therapies.
What could go wrong
This is a very early phase 1 trial with only 42 people, so it is mainly checking safety, not effectiveness. The treatment can cause serious side effects like cytokine release syndrome and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact